Sentence examples for release beads from inspiring English sources

The formulation of sustained release beads was optimized using response surface methodology.

In the present study zidovudine-controlled release beads were prepared with the help of the ionotropic gelation method, using sodium alginate containing KHCO3 as the gas-forming agent.

Further, the interaction between the modified gum and Ca2+-ions was optimized employing a 3-factor, 3-level central composite experimental design to prepare mucoadhesive sustained release beads using metformin hydrochloride as the model drug.

The proposed mathematical model is found to be robust and accurate for optimization of controlled release beads of metformin hydrochloride, consistent with the goals of adequate %entrapment and more than 80% release in 24 h.

Immediate release bead product with a high yield (greater than 60% of 1 mm diameter beads) and low friability (mass loss less than 4.0%) that were spherical to the naked eye (roundness score less than 1.20) were obtained.

Subsequently, a large-scale study demonstrated excellent results in 826 patients with mild to moderately severe rosacea taking daily doxycycline 40 mg monotherapy (30 mg immediate-release and 10 mg delayed-release beads).

Anti-inflammatory dose doxycycline (Oracea®; Galderma) refers to a specific 40 mg capsule formulation of doxycycline monohydrate containing 30 mg immediate-release and 10 mg delayed-release beads administered once daily and that is devoid of antibiotic activity.

A multilayer extended-release bead methylphenidate capsule (provisional name Aptensio XR™, MPH-MLR) with unique release properties is being investigated for the treatment of ADHD.

Biphentin® (Purdue Pharma, Pickering, Ontario, Canada) uses a multilayer-release bead formulation to provide a rapid initial release of 40% of the total racemic MPH dose followed by delivery of the remaining MPH from a controlled-release core [ 10].

Final ethanol concentration is due mostly to the immobilized cells since the cell concentration in aqueous medium due to the release from beads is negligible when compared to the cell concentration in the beads.

Equasym XL® (Shire Pharmaceuticals Ireland Ltd) [ 30] is a modified-release MPH (MR-MPH) formulation comprising 30% immediate-release coated beads and 70% extended-release coated beads, delivering an initial rapid rise in plasma concentration and a slower rise over about 3 hours, with therapeutic plasma concentrations and efficacy in symptom reduction maintained for about 8 hours.